

# **Premarket Review Considerations for Reprocessed SUDs**

**Barbara Zimmerman  
Office of Device Evaluation**

# Classification

**May 1976 premarket process begins**

- **Three classes I, II, III**
  - **Class I (least risk)**
  - **Class II**
  - **Class III (greatest risk)**

**All devices grouped by generic type  
into one of the three classes**

# Important Dates for Reprocessors:

| Premarket Submission Due Dates |           |                                 |
|--------------------------------|-----------|---------------------------------|
|                                | Due By:   | Must be Cleared or Approved by: |
| Class III                      | 2/14/2001 | 2/14/2002                       |
| Class II non-exempt            | 8/14/2001 | 8/14/2002                       |
| Class I non-exempt             | 2/14/2002 | 8/14/2002                       |

# **Devices Excluded from Reprocessing Enforcement Strategy**

- **Permanently implanted pacemakers (see Compliance Policy Guide, 7124.12)**
- **Hemodialyzers (see specific guidance)**
- **Opened but unused devices**
- **SUDs reprocessed by health care facilities that are NOT hospitals (however, enforcement may be expanded to cover in the future)**

# Premarket Requirements

- **Premarket Notification (510(k))**
  - **21 CFR Part 807**
- **Premarket Approval (PMA)**
  - **21 CFR Part 814**

# 510(k) or PMA?

- **Class III: Submit a premarket approval application (PMA).**
- **Class II: Submit a premarket notification (510(k)), unless device is exempt from premarket requirements.**
- **Class I: no 510(k) or PMA is required except for “reserved” class I devices.**

# Examples of Reprocessed SUD's

| <b>Device</b>                  | <b>Class</b> |
|--------------------------------|--------------|
| Surgical Saw<br>Blades         | I            |
| Electrophysiology<br>Catheters | II           |
| Cardiac Ablation<br>Catheters  | III          |

**Additional devices listed at  
<http://www.fda.gov/cdrh/reuse/1168a.html>**

# PMA vs. 510(k)

- **PMA**
  - valid scientific evidence
  - risk/benefit analysis
- **510(k)**
  - substantial equivalence

# **Reprocessors of SUDs Are Considered to Be Manufacturers**

- **All premarket submissions to be handled the same**
  - **No special considerations or allowances, e.g., expedited review or reduced testing requirements**
  - **No extraordinary review criteria or supplemental evaluations necessary**

# **Specific Considerations for PMA Applications**

- **Data to demonstrate safety & effectiveness**
- **Manufacturing processes (including validation)**
- **Pre-approval inspection required**
- **Manufacturing process in compliance with QSR**

# **510(k) Submission Describes a Device Not a Process**

- **Device adequately described & characterized (through testing)**
- **Demonstrate that reprocessed SUD is substantially equivalent to predicate device**

# **510(k) Submission Describes a Device Not a Process**

- **Manufacturing processes assessed through QSR and FDA inspections**
- **Sterility an important device characteristic**

# **Sterilization and Disinfection Information Should Include**

- **Description of decontamination/  
cleaning processes**
- **Description of validation method for  
cleaning and sterilization/disinfection**
  - **Simulated use protocol should be developed**
  - **Reflect worse case conditions**
  - **Manipulation and simulated use in biological  
soil**

# **Sterilization and Disinfection Information Should Include**

- **Endpoints for cleaning and sterilization/disinfection**
- **Sterility assurance level**
- **Conformance with appropriate recognized standards**
- **Description of packaging materials**

# Performance Tests

- **Device specific - check for appropriate guidance document**
- **Additional tests may be needed to assess effects of reprocessing**
- **Test devices that have gone through simulated use protocol**
- **Include descriptions of tests performed to determine product release, provide pass/fail criteria**

# **Biocompatibility Tests**

- **If needed for OEM device, will be needed for reprocessed devices**
- **Cleaning and sterilization agents may adversely affect device materials and biocompatibility**

# Biocompatibility Tests

- Testing should be done under worst case conditions (maximum times device is to be reprocessed; include exposure to simulated use).
- See specific ODE guidance document on biocompatibility testing.

# Shelf Life Tests

- **If needed for OEM device, will be needed for reprocessed device**
- **Evaluate and document stability under worse case conditions**
  - **should reflect exposure to simulated use protocol and maximum number of times device can be reprocessed**

# Labeling

- Labeling (device description, indications for use, adequate directions for use) are required for all devices cleared under 510(k).
- Labeling must include reprocessor's name, address and other contact information.
- Labeling must be included with the device (not on file at the hospital or user facility).

# **Can One 510(k) Cover Multiple Devices?**

- **Yes, if devices would be included in one 510(k) by the OEM**
- **Bundled devices w/same indications for use**
- **Reprocessors could propose specifications for a device that encompasses models from more than one OEM**

# To Expedite Review

- **In cover letter identify as a premarket submission for reprocessed SUD.**
- **Consider using special and abbreviated 510(k)s.**
- **Submit master files if information can be used in multiple submissions.**
- **Pre-submission meetings and teleconferences may be useful.**

# Office of Device Evaluation

```
graph TD; A[Office of Device Evaluation] --> B[Div. of Dental, Infection Control, & General Hospital Devices]; A --> C[Div. of Reproductive, Abdominal, & Radiological Devices]; A --> D[Div. of General, Restorative & Neurological Devices]; A --> E[Div. of Ophthalmic & ENT Devices]; A --> F[Div. of Cardiovascular & Respiratory Devices]; A --> G[Div. of Clinical Laboratory Devices];
```

**Div. of Dental,  
Infection Control,  
& General  
Hospital Devices**

**Div. of Reproductive,  
Abdominal, &  
Radiological Devices**

**Div. of General,  
Restorative &  
Neurological  
Devices**

**Div. of  
Cardiovascular  
& Respiratory  
Devices**

**Div. of Ophthalmic  
& ENT Devices**

**Div. of Clinical  
Laboratory Devices**

# Contact Persons

- **Coordination of Reuse Policy in ODE  
(premarket issues only)**
  - **Philip J. Phillips (301) 594-2022**
  - **Timothy A. Ultatowski (301) 443-8879**
  - **Heather Rosecrans (301) 594-1190**
  - **Barbara Zimmerman (301) 594-2036**

# Guidance Documents

- **Specific for Reprocessors**
  - **“Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals”**

**[www.fda.gov/cdrh/reuse/1168.html](http://www.fda.gov/cdrh/reuse/1168.html)**

- **“Frequently Asked Questions on Reuse of Single Use Devices”**

**[www.fda.gov/cdrh/reuse/reuse-faq.shtml](http://www.fda.gov/cdrh/reuse/reuse-faq.shtml)**

# Guidance Documents

- **Specific for Reprocessors**
  - **Letter to Hospitals Re: Reprocessing of Single Use Devices - 4/23/01**  
**[www.fda.gov/cdrh/reuse/042301\\_reuse.html](http://www.fda.gov/cdrh/reuse/042301_reuse.html)**
  - **Compliance Policy Guide (CPG 7124.16) Section 300.500. Reuse of Medical Disposable Devices - 9/24/87**  
**[www.fda.gov/cdrh/comp/cpgreuse.pdf](http://www.fda.gov/cdrh/comp/cpgreuse.pdf)**

# Guidance Documents

- **Biocompatibility**
  - “Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing'”

[www.fda.gov/cdrh/g951.html](http://www.fda.gov/cdrh/g951.html)

# Guidance Documents

- **Reusable Devices**
  - **“Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities: FDA Reviewer Guidance”**  
**[www.fda.gov/cdrh/ode/198.pdf](http://www.fda.gov/cdrh/ode/198.pdf)**

# Guidance Documents

- **Reusable Devices**
  - **“Questions & Answers for the FDA Reviewer Guidance: Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities”**

**[www.fda.gov/cdrh/ode/1198.html](http://www.fda.gov/cdrh/ode/1198.html)**

# Guidance Documents

- **Use of Standards in 510(k)s**

- **“Use of Standards in Substantial Equivalence Determinations”**

- [\*\*www.fda.gov/cdrh/ode/guidance/1131.html\*\*](http://www.fda.gov/cdrh/ode/guidance/1131.html)

- **“Guidance on the Recognition and Use of Consensus Standards”**

- [\*\*www.fda.gov/cdrh/modact/k982.html\*\*](http://www.fda.gov/cdrh/modact/k982.html)

# Guidance Documents

- **Use of Standards in 510(k)s**
  - **“Frequently Asked Questions on Recognition of Consensus Standards”**

**[www.fda.gov/cdrh/modact/faqost.html](http://www.fda.gov/cdrh/modact/faqost.html)**

# Guidance Documents

- Abbreviated and Special 510(k)s
  - “A New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications”

[www.fda.gov/cdrh/ode/parad510.html](http://www.fda.gov/cdrh/ode/parad510.html)

- “Frequently Asked Questions on the New 510(k) Paradigm”

[www.fda.gov/cdrh/ode/92\\_a.html](http://www.fda.gov/cdrh/ode/92_a.html)

# Guidance Documents

- **Sterilization**
  - **“Updated 510(k) Sterility Review Guidance K90-1; Final Guidance for Industry and FDA”**

[www.fda.gov/cdrh/ode/guidance/361.pdf](http://www.fda.gov/cdrh/ode/guidance/361.pdf)